Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II interventional trial for the assessment of histological responses in all resected colorectal cancer liver metastases after preoperative cetuximab-based chemotherapy. [Ensayo clinico fase II para la evaluacion de las respuestas histologicas de todas las metastasis hepaticas resecadas en pacientes con Cancer colorectal metastasico tras quimioterapia preoperatoria basada en Cetuximab]

Trial Profile

Phase II interventional trial for the assessment of histological responses in all resected colorectal cancer liver metastases after preoperative cetuximab-based chemotherapy. [Ensayo clinico fase II para la evaluacion de las respuestas histologicas de todas las metastasis hepaticas resecadas en pacientes con Cancer colorectal metastasico tras quimioterapia preoperatoria basada en Cetuximab]

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Liver metastases
  • Focus Therapeutic Use
  • Acronyms ERBIMET
  • Most Recent Events

    • 07 Dec 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 10 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top